Stevanato (STVN)
Discovery Club, by Mark Robertson, Managing Partner September 20th, 2023
As we begin the hunt for this year’s collection of Best Small Companies, Ken Kavula found this candidate that produces a product with an enormous/expanding field of opportunity and execution/reliability that seems to be place STVN on the speed dial of a very significant number of major pharmaceutical companies. Their products already touch many of us and they’re expanding production (Fishers, Indiana) and business development in the United States.
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.
The company web site provides a current (9/13/2023) investor presentation that provides a solid overview of the company:
Stevanato: Managing Complexity, Delivering Value (September 13, 2023)
Equity Analysis (STVN)
Business Description
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.
Mark Robertson
Mark Robertson is founder and managing partner of Manifest Investing, a source for research and portfolio management focusing on strategic long term investors.